Data / Drug companies / Mylan Pharmaceuticals Inc.
Mylan Pharmaceuticals Inc.: 78 products in the FDA NDC directory, labeler code 59762
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Mylan Pharmaceuticals Inc. (labeler code 59762) lists 78 products in the FDA National Drug Code Directory, covering 36 finished drugs by generic name. By type: 78 prescription drugs. Its main marketing category is authorized generics (NDA). The newest product started marketing on August 3, 2026.
The request: Watch Mylan Pharmaceuticals Inc. (FDA labeler code 59762): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 59762
- Products in commercial distribution
- 78
- Packages
- 110
- Finished drugs by generic name
- 36
- Prescription products
- 78
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 10, Schedule V 2
- Flagged as original packager
- 75 of 75 products that carry the flag
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 4
- Earliest marketing start
- June 3, 1959
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Authorized generics (NDA) | 77 | 98.7% |
| Generic drugs (ANDA) | 1 | 1.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 78 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 39 | 50% |
| Tablet, film coated | 10 | 12.8% |
| Tablet, extended release | 4 | 5.1% |
| Tablet, sugar coated | 4 | 5.1% |
| Solution | 4 | 5.1% |
| Powder, for suspension | 3 | 3.8% |
| Suspension | 3 | 3.8% |
| Capsule, gelatin coated | 2 | 2.6% |
| Tablet, delayed release | 2 | 2.6% |
| Cream | 2 | 2.6% |
| Granule, for suspension | 1 | 1.3% |
| Lotion | 1 | 1.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Doxazosin mesylate | 59762-1391 | Tablet | Authorized generics (NDA) | August 3, 2026 |
| Doxazosin mesylate | 59762-1390 | Tablet | Authorized generics (NDA) | September 24, 2025 |
| Doxazosin mesylate | 59762-1389 | Tablet | Authorized generics (NDA) | May 9, 2025 |
| Doxazosin mesylate | 59762-1388 | Tablet | Authorized generics (NDA) | May 9, 2025 |
| Eplerenone | 59762-1107 | Tablet, film coated | Authorized generics (NDA) | December 13, 2024 |
| Eplerenone | 59762-1108 | Tablet, film coated | Authorized generics (NDA) | November 14, 2024 |
| Doxazosin | 59762-2440 | Tablet | Authorized generics (NDA) | January 18, 2023 |
| Gabapentin | 59762-5050 | Suspension | Authorized generics (NDA) | July 1, 2022 |
| Doxazosin | 59762-2480 | Tablet | Authorized generics (NDA) | October 19, 2021 |
| Doxazosin | 59762-2420 | Tablet | Authorized generics (NDA) | October 19, 2021 |
| Phenytoin | 59762-0531 | Suspension | Authorized generics (NDA) | April 22, 2020 |
| Ethosuximide | 59762-2350 | Solution | Generic drugs (ANDA) | February 21, 2020 |
| Pregabalin | 59762-1576 | Solution | Authorized generics (NDA) | July 29, 2019 |
| Sirolimus | 59762-1205 | Solution | Authorized generics (NDA) | July 22, 2019 |
| Amlodipine besylate | 59762-2242 | Tablet | Authorized generics (NDA) | June 24, 2019 |
| Amlodipine besylate | 59762-2135 | Tablet | Authorized generics (NDA) | June 24, 2019 |
| Amlodipine besylate | 59762-2010 | Tablet | Authorized generics (NDA) | June 24, 2019 |
| Liothyronine Sodium | 59762-1208 | Tablet | Authorized generics (NDA) | June 24, 2019 |
| Liothyronine Sodium | 59762-1207 | Tablet | Authorized generics (NDA) | June 24, 2019 |
| Disopyramide Phosphate | 59762-0400 | Capsule, gelatin coated | Authorized generics (NDA) | April 23, 2019 |
| Disopyramide Phosphate | 59762-0386 | Capsule, gelatin coated | Authorized generics (NDA) | April 23, 2019 |
| Liothyronine Sodium | 59762-1206 | Tablet | Authorized generics (NDA) | February 6, 2019 |
| Medroxyprogesterone acetate | 59762-0058 | Tablet | Authorized generics (NDA) | August 20, 2018 |
| Medroxyprogesterone acetate | 59762-0055 | Tablet | Authorized generics (NDA) | August 19, 2018 |
| Sertraline hydrochloride | 59762-0067 | Solution, concentrate | Authorized generics (NDA) | May 15, 2018 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.